Klotsche J, Klein A, Niewerth M, et al. - This study draws on data from two ongoing prospective registries, BiKeR and JuMBO, to determine correlates for etanercept (ETA) discontinuation after achieving an inactive disease and for the subsequent risk of flare and to analyze the effectiveness of ETA in the re-treatment after a disease flare. In total, 1,724 patients were treated first with ETA treatment course (338 with second, 54 with third ETA course). Younger age, persistent oligoarthritis, and shorter duration between juvenile idiopathic arthritis (JIA) onset and ETA start, as well as a good response to therapy within the first 6 months of treatment significantly associated with discontinuation with inactive disease. Even for re-treatment of JIA patients, the study confirms the efficacy of ETA. The findings show a connection between early biologic disease-modifying anti-rheumatic drug treatment and a higher incidence of inactive disease, suggesting a potential window of opportunity.